Company performance
Add to research
Current Price
as of May 12, 2025$73.63
P/E Ratio
N/A
Market Cap
$5.29B
Description
Add to research
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Metrics
Add to research
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerNUVL
- Price$73.63+5.41%
Trading Information
- Market cap$5.29B
- Float61.95%
- Average Daily Volume (1m)633,794
- Average Daily Volume (3m)619,706
- EPS-$4.40
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$84.58M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$94.81M
- EV$4.01B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B5.23
- Debt/EquityN/A
Documents
Add to research
SEC Filings
Factset Street Account